City Therapeutics Appoints Andy Orth as Chief Executive Officer - Marketscreener.com
| KRYS Stock | USD 148.39 3.58 2.47% |
Slightly above 55% of Krystal Biotech's private investors are presently thinking to get in. The analysis of the overall investor sentiment regarding Krystal Biotech suggests that some traders are interested. Krystal Biotech's investing sentiment can be driven by a variety of factors including economic data, Krystal Biotech's earnings reports, geopolitical events, and overall market trends.
Krystal |
City Therapeutics Appoints Andy Orth as Chief Executive Officer Marketscreener.com
Read at news.google.com
 |
Krystal Biotech Fundamental Analysis
We analyze Krystal Biotech's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Krystal Biotech using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Krystal Biotech based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Gross Profit
Gross Profit Comparative Analysis
Krystal Biotech is currently under evaluation in gross profit category among its peers. Gross Profit is the most basic measure of business operational efficiency. It is simply the difference between sales revenue and the cost associated with making a product or providing a service. It is calculated before deducting administrative expenses, taxes, and interest payments.
Krystal Biotech Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Krystal Biotech stock to make a market-neutral strategy. Peer analysis of Krystal Biotech could also be used in its relative valuation, which is a method of valuing Krystal Biotech by comparing valuation metrics with similar companies.
Peers
Krystal Biotech Related Equities
| MGTX | MeiraGTx Holdings | 5.56 | ||||
| RGNX | Regenxbio | 3.08 | ||||
| APLS | Apellis Pharmaceuticals | 0.71 | ||||
| RYTM | Rhythm Pharmaceuticals | 0.22 |
Additional Tools for Krystal Stock Analysis
When running Krystal Biotech's price analysis, check to measure Krystal Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Krystal Biotech is operating at the current time. Most of Krystal Biotech's value examination focuses on studying past and present price action to predict the probability of Krystal Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Krystal Biotech's price. Additionally, you may evaluate how the addition of Krystal Biotech to your portfolios can decrease your overall portfolio volatility.